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REDUCING COSTS WITHOUT COMPROMISING QUALITY IN THE PEDI-
ATRIC ALLOGENEIC TRANSPLANTATION SETTING
Fisher, V.L.1, Ellerbrock, K.1, Casey, F.1, Nieder, M.2 1Rainbow Babies
and Children’s Hospital, Cleveland, OH; 2All Children’s Hospital, St.
Petersburg, FL.
Blood and marrow transplantation (BMT) is a costly procedure.
In 1998, we began to institute practices aimed at reducing costs
without compromising quality and outcomes. These changes in
our practice were introduced sequentially over a 4-year period.
Several cost reducing strategies were used, including eliminating
weekly chest radiographs, limiting laboratory tests, replacing total
parenteral nutrition with enteral tube feedings (in 2001), addition
of glutamine (in 1999), and replacing intravenous tacrolimus with
oral tacrolimus for graft-versus-host disease (GVHD) prevention.
The outcomes of 78 consecutive allogeneic BMTs performed be-
tween 1995 and 2004 were analyzed. Parameters for analysis in-
cluded GVHD, day 100 survival, overall survival, engraftment,
relapse-free survival, days in the pediatric intensive care unit,
bacteremia, veno-occlusive disease of the liver, and transplanta-
tion-related mortality. There was no signiﬁcant difference in any
outcome parameter when each of the practice changes was ana-
lyzed separately or even when taken together. This suggests that
institutional supportive care practices should be periodically re-
viewed for their value, effect on patient care, burden to nursing
staff, and discomfort to the patient. Future studies analyzing time
and cost savings by point-of-care practitioners should focus on
those intensive practices that are not based on sound medical
evidence.
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GANCICLOVIR AND HIGH-DOSE VALACYCLOVIR REDUCE CYTOMEGA-
LOVIRUS REACTIVATION IN PATIENTS RECEIVING ALLOGENEIC STEM
CELL TRANSPLANTATION WITH CAMPATH-1H–BASED CONDITIONING
REGIMENS
Kline, J.P., Pollyea, D., Artz, A.S., Stock, W., Rich, E., Godley, L.A.,
Zimmerman, T., van Besien, K. The University of Chicago Hospitals,
Chicago, IL.
Campath-1H (alemtuzumab)-based conditioning regimens are
associated with rates of CMV reactivation as high as 50%-85% in
seropositive donor/recipient pairs. A high incidence of adenovirus
infection has been reported as well. It is known that prophylactic
use of high-dose acyclovir reduces the incidence of CMV viremia.
Recently, a randomized evaluation of high-dose oral valacyclovir in
patients receiving myeloablative stem cell transplantation revealed
a further reduction in the incidence of CMV viremia. We evalu-
ated 95 patients receiving an allogeneic SCT and conditioned with
ﬂudarabine 30 mg/m2/day (on days 7 to 3), alemtuzumab 20
mg/day (on days7 to3), and melphalan 140 mg/m2/day (on day
2). CMV reactivation was deﬁned as 1 positive polymerase
chain reaction (PCR) for CMV, positive antigen test, or culture.
The initial 11 patients received prophylaxis with high-dose acyclo-
vir 500 mg/m2 every 8 hours from day 7 until engraftment,
followed by 800 mg 4 times daily until day 180.
Seven of the initial 11 patients developed CMV reactivation.
There was also 1 questionable case of CMV disease in a patient
who died of respiratory failure. Autopsy revealed alveolar cells
positive for CMV and urine positive for adenovirus. The subse-
quent 84 patients received prophylaxis with ganciclovir 5 mg/kg
twice daily from day 7 to day 2, acyclovir 500 mg/m2 every 8
hours from day 2 until engraftment, followed by valacyclovir 2 g
4 times daily until day 210.
The cumulative incidence of CMV reactivation in the 84 patients
receiving prophylaxis with ganciclovir and valacyclovir was only
17%  9% (14 of 84 total patients) by day 100 and 20%  10%
by day 250. There were no cases of CMV disease. Interestingly,
there was only 1 case of adenovirus infection, in a patient who
refused valacyclovir.
In summary, CMV prophylaxis with ganciclovir followed by
valacyclovir is effective in decreasing the incidence of CMV reac-
tivation after Campath-1H–based conditioning regimens, and may
also decrease the incidence of adenovirus disease.
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RESPIRATORY SYNCYTIAL VIRUS INFECTIONS IN ALLOGENEIC HSCT
PATIENTS: EFFECTIVE ANTIVIRAL THERAPY ELIMINATES ACUTE MOR-
TALITY, BUT INFECTION-RELATED LUNG INJURY MAY PREDISPOSE TO
SUBSEQUENT PULMONARY COMPLICATIONS
Quinones, R.1,2, Hild, E.2, Malcolm, J.2, Foreman, N.1,2, Garcea, R.1,2,
Gore, L.1,2, Peltz, A.1,2, Pasut, B.2, Van Stelle, J.2, Adams, J.2,
Giller, R.1,2 1University of Colorado School of Medicine, Denver, CO;
2The Children’s Hospital, Denver, CO.
Community-acquired respiratory viral infections in allogeneic
HSCT patients are frequently life-threatening. Much of the mor-
tality is due to acute viral infection, for which there is often
inadequate therapy to prevent upper respiratory infection (URI)
from progressing to pneumonia or to treat established viral pneu-
monia.
We retrospectively analyzed 128 allogeneic HSCT patients to
identify those who developed RSV infections (URI or lower respi-
ratory infection [LRI]). A total of 37 patients (29%) were diag-
nosed with RSV by clinical respiratory symptoms, microbiology
studies (DFA, EIA, culture), and radiology studies. Patients with
LRI and/or high-risk URI (unrelated, nongenotypic family grafts)
were treated with inhaled Ribavirin and either RSV-IgG or Syna-
gis™  high-dose IgG. Thirty-three of 37 patients survived the
RSV infection, clearing the RSV (RSV studies negative  2 or
negative at autopsy). RSV was not the primary cause of death in
any patient and cleared in 13 of 16 patients based on clinical course
or by autopsy. Three patients had had other primary pathology
(extensive invasive aspergillosus, CMV pneumonia, or MOF) but
had viropathic changes at autopsy and were RSV culture negative.
Day 100 and 1-year survivals were 78% and 75% in RSV patients
and 80% and 55% in RSV patients (P  not signiﬁcant). Al-
though RSV infection could be successfully eradicated with ther-
apy, deaths in 12 of 16 of these patients were related to subsequent
pulmonary complications (hemorrhage in 6 and IPS/GVHD in 6).
Among the RSV survivors (median follow-up, 1484 days), 18 of 21
had subsequent pulmonary complications, including immune-me-
diated lung disease (13 with IPS, chronic pulmonary GVHD,
and/or BOOP). These nonfatal pulmonary complications clinically
resolved in 10 patients and remain quiescent in 3 patients. Eight of
the 21 patients developed chronic lung disease, primarily reactive
airway disease/asthma.
RSV respiratory infections are relatively common in pediatric
allogeneic HSCT patients. The active infection can usually be
eradicated with inhaled ribavirin and serotherapy. However, de-
spite microbiologic clearing of RSV, signiﬁcant residual lung in-
jury may persist and predispose patients to subsequent, potentially
fatal, postinfectious pulmonary complications or chronic lung dis-
ease. This suggests that future efforts should not only seek to
optimize viral diagnosis and antiviral therapy, but also to control
postinfectious inﬂammatory processes that may lead to further
subsequent lung injury.
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